| human | Q5 |
| P496 | ORCID iD | 0000-0001-5049-1379 |
| P69 | educated at | Autonomous University of Barcelona | Q43452 |
| P106 | occupation | researcher | Q1650915 |
| Q44530942 | Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study |
| Q90689589 | Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men |
| Q42879806 | Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir |
| Q90409234 | Evaluation of Potential Pain Biomarkers in Saliva and Pain Perception After Corneal Advanced Surface Ablation Surgery |
| Q91252047 | Incidence of cervical high-grade squamous intraepithelial lesions in HIV-1-infected women with no history of cervical pathology: up to 17 years of follow-up |
| Q42689409 | Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. |
| Q90026287 | Routine screening of anal cytology in HIV-infected subjects and the impact on invasive anal cancer. A prospective cohort study |
| Q47169054 | Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects |
| Q64883547 | The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers. |
| Q43102288 | Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients. |
| Q54656230 | [Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]. |
Search more.